Dual-Action 5-HT1A and SSRI Derivatives for Neurological Disorders
Solution Overview
Problem
Current treatments for neurological disorders such as depression, anxiety, and schizophrenia lack effective dual-action compounds that simultaneously target 5-HT 1A receptors and serotonin reuptake inhibitors, leading to suboptimal therapeutic outcomes and side effects.
Innovation Solution
Development of a novel compound, specifically N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives with dual activities as 5-HT 1A receptor ligands and selective serotonin reuptake inhibitors, which can be used to treat various neurological and psychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate medications for 5-HT1A receptor and serotonin reuptake are used, then therapeutic coverage is comprehensive, but treatment complexity and side effects increase
Solution Approach 1:
The patent combines two separate pharmacological functions (5-HT1A receptor agonism and serotonin reuptake inhibition) into a single dual-action compound. This merging approach allows the compound to simultaneously target both mechanisms, providing comprehensive therapeutic coverage for depression and anxiety while reducing treatment complexity and potential drug-drug interactions compared to using separate medications
Solution Approach 2:
The compound exhibits multi-functionality by acting as both a 5-HT1A receptor agonist and a serotonin reuptake inhibitor. This universal action across multiple targets within the serotonin system enables the single compound to address multiple aspects of mood and anxiety disorders, replacing the need for multiple specialized medications
2Productivity
If dual-action compounds are developed, then therapeutic efficiency is enhanced, but drug development complexity increases
Solution Approach 1:
The drug development process merged two distinct pharmacological activities into a single molecular entity. By combining the 5-HT1A agonist pharmacophore with the serotonin reuptake inhibitor structural features, the researchers created a dual-action compound that delivers enhanced therapeutic efficiency through simultaneous multi-target engagement
Solution Approach 2:
The dual-action compound represents a composite molecular structure integrating features of both 5-HT1A agonists and SSRIs. This composite design allows the molecule to interact with multiple biological targets, achieving synergistic therapeutic effects that exceed the sum of individual single-action compounds
3Ease of operation
If conventional single-action medications are used, then drug simplicity is maintained, but onset time and therapeutic effect are limited
Solution Approach 1:
The patent maintains drug simplicity by using a single oral medication rather than multiple drugs, while simultaneously accelerating onset time through dualmechanism action. The combined 5-HT1A agonism and serotonin reuptake inhibition provide rapid initial anxiolytic and antidepressant effects, reducing the waiting period for therapeutic response compared to conventional single-action medications
Data Source
Figure 1~2
Figure 3
AI summary
Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.
